Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice

Scandinavian Journal of Immunology

Volumn 83, Issue 2, 2016, Pages 109-118

  Matsushita, N ^a   Osaka, T ^a,b   Haruta, I ^a   Ueshiba, H ^a   Yanagisawa, N ^a   Omori Miyake, M ^a   Hashimoto, E ^a   Shibata, N ^a   Tokushige, K ^a   Saito, K ^a   Tsuneda, S ^b   Yagi, J ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b WASEDA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; FREUND ADJUVANT; LIPOPOLYSACCHARIDE; RNA 16S; BACTERIAL RNA; CYTOKINE; MESSENGER RNA;

ACTINOBACTERIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEROIDACEAE; BACTEROIDALES; BACTEROIDETES; CELL INFILTRATION; COLON FLORA; CONTROLLED STUDY; DEFERRIBACTERES; DIET; DISEASE COURSE; DYSBIOSIS; ERYSIPELOTRICHACEAE; FIRMICUTES; HIGH CALORIC DIET; LIVER FIBROSIS; MALE; MOLLICUTES; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PEPTOSTREPTOCOCCACEAE; PRIORITY JOURNAL; PROTEOBACTERIA; PYROSEQUENCING; TISSUE HOMOGENATE; UPREGULATION; VERRUCOMICROBIA; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CALORIC INTAKE; COLON; DISEASE MODEL; GENETICS; IMMUNOLOGY; INTESTINE FLORA; ISOLATION AND PURIFICATION; LIVER; METABOLISM; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; COLON; CYTOKINES; DIET; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENERGY INTAKE; GASTROINTESTINAL MICROBIOME; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA, BACTERIAL; RNA, MESSENGER; RNA, RIBOSOMAL, 16S;

EID: 84955616639     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12397     Document Type: Article

References (38)

1. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007;46:716-22.
2. Van der Poorten D, Milner KL, Hui J et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008;48:449-57.
3. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012;3:279-88.
4. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-46.
5. Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic? Hepatol Res 2012;42:1-14.
6. Wieser V, Moschen AR, Tilg H. Adipocytokines and hepatocellular carcinoma. Dig Dis 2012;30:508-13.
7. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5.
8. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-38.
9. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. Q J Med 2010;103:71-83.
10. Yilmaz Y. Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012;36:815-23.
11. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013;19:338-48.
12. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 2013;24:537-45.
13. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-72.
14. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-81.
15. Farhadi A, Gundlapalli S, Shaikh M et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008;28:1026-33.
16. Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87.
17. Henao-Mejia J, Elinav E, Jin C et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-85.
18. Miura K, Kodama Y, Inokuchi S et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010;139:323-34.
19. Miura K, Seki E, Ohnishi H, Brenner DA. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol Res Pract 2010;2010:362847.
20. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007;56:1986-98.
21. Dapito DH, Mencin A, Gwak GY et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-16.
22. Liu Z, Lozupone C, Hamady M, Bushman FD, Knight R. Short pyrosequencing reads suffice for accurate microbial community analysis. Nucleic Acids Res 2007;35:e120.
23. Cole JR, Wang Q, Cardenas E et al. The ribosomal database project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res 2009;37:D141-5.
24. Wan J, Benkdane M, Teixeira-Clerc F et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014;59:130-42.
25. Arai S, Miyazaki T. Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases. Semin Immunopathol 2014;36:3-12.
26. Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: current concepts and remaining challenges. Hepatol Res 2015;45:20-8.
27. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.
28. Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun 2013;46:66-73.
29. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:691-701.
30. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-84.
31. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002;60:289-93.
32. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006;26:1021-8.
33. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9.
34. Wagnerberger S, Spruss A, Kanuri G et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012;107:1727-38.
35. Eisenbarth SC, Williams A, Colegio OR et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 2012;484:510-3.
36. Backhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-23.
37. Mouzaki M, Comelli EM, Arendt BM et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013;58:120-7.
38. Ivanov II, Atarashi K, Manel N et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-98.